Art. -Nr.: HY-112829

Denifanstat

(Synonyms: TVB-2640; FASN-IN-2; ASC-40)

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC₅₀ of 0.052 μM and an EC₅₀ of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.58%
CAS. Nr.: 1399177-37-7
Formel: C₂₇H₂₉N₅O
Molecular Weight:439.55

Speicherung:

4°C, protect from light

* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

Denifanstat Chemical Structure

CAS. Nr.: 1399177-37-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- Clinical Trial
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 0.052 μM (FASN)^[1]

In Vitro

Denifanstat (compound 152) is a potent FASN inhibitor^[2].
Fatty Acid Synthase (FASN) inhibition prevents palmitoylation of SARS-CoV2 spike protein^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1399177-37-7
Appearance Solid
Molecular Weight 439.55
Formel C₂₇H₂₉N₅O
Color White to off-white
SMILES

N#CC1=CC=C(C2CCN(C(C3=CC(C4=NC(C)=NN4)=C(C5CCC5)C=C3C)=O)CC2)C=C1
Synonyms

TVB-2640; FASN-IN-2; ASC-40
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

Publications (8)

All IFIn Vivo Efficacy StudyRT-PCR

Sort by:

Journal Impact Factor

Cancer Cell

Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma. [Abstract]

2026 Feb 9;44(2):383-404.e18. PMID: 41544627
Cancer Commun (Lond)

Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. [Abstract]

2025 Aug;45(8):1010-1037. PMID: 40439109

Denifanstat purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Aug;45(8):1010-1037. [Abstract]

Denifanstat (10 mg/kg; i.g.; every day; from day7 to day20); Lovastatin(10 mg/kg; i.g.; every day; from day7 to day20); Simvastatin (50 mg/kg; i.g.; every day; from day7 to day20). Tumor growth curve of each group (4 mice/group). ns, not significant; * P < 0.05, **P < 0.01, ***P < 0.001.
Nat Metab

Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. [Abstract]

2021 Nov;3(11):1466-1475. PMID: 34580494

Denifanstat purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Nov;3(11):1466-1475. [Abstract]

Fatty acid synthase inhibitors suppress SARS-CoV-2 virus replication. Representative fluorescence images of SARS-CoV-2-mNG infected multiple cell lines. Indicated cells were pre-treated with Denifanstat (TVB-2640) (1-2 µM) at the following concentration: NCI-H1355 and NCI-1437 (2 µM); Caco-2 (2 µM); MEF-hACE2 (1 µM), from 16 h before infection and then infected with SARS-CoV-2-mNG at an MOI = 0.1(NCI-H1355, NCI-1437), MOI = 0.05 (Caco-2), MOI = 0.01 (MEF-hACE2). Fluorescence images were acquired at 48 hpi. Hoechst 33342 was used for nuclear staining. Scale bar: 200 μm.

Denifanstat purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Nov;3(11):1466-1475. [Abstract]

Palmitic acid reverses the effects of knockout and inhibition of fatty acid synthase on viral replication. Representative fluorescence images of palmitoylated protein assay. HEK293T-hACE2 and NCI-H1355 cells were treated with Denifanstat (TVB-2640)100 nM; NCI-H1355 cells: Denifanstat (TVB-2640) 2 µM for 24 h and the EZClick palmitic acid label was added to the medium for another 24 h. Cells were then processed and analyzed by microscopy following the manufacturer's instruction. Scale bar: 40 μm.

Denifanstat purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Nov;3(11):1466-1475. [Abstract]

Denifanstat (TVB-2640) reduces body weight loss and prolongs mouse survival after SARS-CoV-2 infection. K18-hACE2 transgenic mice were infected with SARS-CoV-2 virus and i.p. injected with TVB-2640 (8 mg/kg; i.p.; from day 0 to day 5.

Denifanstat purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Nov;3(11):1466-1475. [Abstract]

Fatty acid synthase inhibitors suppress the replication of SARS-CoV-2 variants. NCI-H1355 cells were pre-treated with Denifanstat (TVB-2640) (2 µM) for 16 h and infected with SARS-CoV-2 variants with an MOI of 0.1. The cells were analyzed by qPCR for viral RNA at 48 hpi.
J Adv Res

Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma. [Abstract]

2025 Aug 8:S2090-1232(25)00596-X. PMID: 40784518
Cell Death Dis

The OAS1-FASN axis promotes pancreatic cancer by coordinating lipogenic stress and the unfolded protein response. [Abstract]

2026 Jun 3. PMID: 42236684
J Ethnopharmacol

Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors. [Abstract]

2026 Feb 28:357:120890. PMID: 41232632
bioRxiv

2026 Feb 1.
bioRxiv

2024 August 23.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (227.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2751 mL

11.3753 mL

22.7505 mL

5 mM

0.4550 mL

2.2751 mL

4.5501 mL

10 mM

0.2275 mL

1.1375 mL

2.2751 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Minhyoung Lee, et al. Fatty Acid Synthase inhibition prevents palmitoylation of SARS-CoV2 Spike Protein and improves survival of mice infected with murine hepatitis virus. BioRxiv, December 21, 2020.

[2]. Johan D., et al. Heterocyclic modulators of lipid synthesis. WO2012122391A1.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2751 mL	11.3753 mL	22.7505 mL	56.8764 mL
	5 mM	0.4550 mL	2.2751 mL	4.5501 mL	11.3753 mL
	10 mM	0.2275 mL	1.1375 mL	2.2751 mL	5.6876 mL
	15 mM	0.1517 mL	0.7584 mL	1.5167 mL	3.7918 mL
	20 mM	0.1138 mL	0.5688 mL	1.1375 mL	2.8438 mL
	25 mM	0.0910 mL	0.4550 mL	0.9100 mL	2.2751 mL
	30 mM	0.0758 mL	0.3792 mL	0.7584 mL	1.8959 mL
	40 mM	0.0569 mL	0.2844 mL	0.5688 mL	1.4219 mL
	50 mM	0.0455 mL	0.2275 mL	0.4550 mL	1.1375 mL
	60 mM	0.0379 mL	0.1896 mL	0.3792 mL	0.9479 mL
	80 mM	0.0284 mL	0.1422 mL	0.2844 mL	0.7110 mL
	100 mM	0.0228 mL	0.1138 mL	0.2275 mL	0.5688 mL

Keywords

Denifanstat

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Denifanstat

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Denifanstat

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Denifanstat

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Denifanstat

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Denifanstat Related Classifications

HY-112829 Related Classifications